Overview
Introduction
The antipsychotic market is worth an estimated $10.7 billion and is led by Eli Lilly's blockbuster Zyprexa. After 2007, the market is expected to plateau due to the genericization of Janssen's Risperdal and Pfizer's Geodon. However, Bristol-Myers Squibb's dopaminergic modulator Abilify, launched in 2002. Has acheived good uptake and is predicted to reach blockbuster status by 2009.
Scope
- Detailed coverage of the patient potential, unmet needs, and clinical trial design of antipsychotics across the seven major markets
- Overview of drugs in preregistration, Phase III, II, I and preclinical development, with in-depth profiles of Organon and Sanofi-Synthelabo
- Profiles of compounds undergoing development for schizophrenia, with sales forecasts to 2011
- Insight into current research for novel diagnostic tests and the genetic basis of psychosis
Report Highlights
The current late stage antipsychotic pipeline is unlikely to yield a blockbuster product over the forecast period. Novartis has discontinued research of Zomaril with the drug now available for out-licensing, leaving NovartisEantipsychotic pipeline empty.
Lundbeck's Serdolect is set for relaunch in 2005, with post-marketing studies demonstrating that the drugs efficacy and safety profile is comparable to current frontline antipsychotics. However, Datamonitor is unsure whether this is enough to dispel the negative association with heart problems.
Novel neurotransmitter receptor ligands form the majority of drugs in Phase II and below. Due to the predicted high specificity and narrowed spectrum of efficacy, Datamonitor believes these compounds will be investigated as adjuncts, as a precursor to the predicted future of polytherapy. | 
View Cart
